title: [Detection and clinical pathological significance of the expression of P21, P185, p53 proteins and mutation of ras, p53 genes in transitional cell carcinoma of the bladder].
abstract: In order to find the significance of gene changes in the development of transitional cell carcinoma of bladder, immunohistochemical and PCR-RFLP methods were used to study the expression of P21, P185, p53 proteins and mutations in ras and p53 genes. The results showed that the P21, P185 and p53 positive rates were 59.3%, 55.3% and 29.3% respectively. Positive rates for P21 and P185 decreased with the progression of the pathological grade (P < 0.05). p53 positive rates decreased with the progression of pathological grade (P < 0.01). Positive expression of P21, P53 were significantly correlated with prognosis. Expression of more than two kinds of oncogene proteins were present in 73 cases of bladder transitional cell carcinoma. The rate of point mutation in codon 12 of Ha-ras gene of bladder transitional cell carcinoma was 32%. The p53 gene mutation rate of bladder transitional cell carcinoma was 18%, all mutations occurred at codon 248. The point mutation in codon 12 of Ha-ras gene increased with the progression of pathological grade (P < 0.05). The ras and p53 gene mutations were significantly correlated with prognosis (P < 0.05). The mortality of patients with ras and p53 gene mutation were higher than patients without mutations. 4 cases of bladder transitional cell carcinoma contained both ras and p53 gene mutations.
authors.affiliation: Department of Pathology, Southwest Hospital, Third Military Medical University, Chongqing.
authors.forename: D
authors.initials: D
authors.lastname: Yu
authors.forename: F
authors.initials: F
authors.lastname: Liu
authors.forename: Z
authors.initials: Z
authors.lastname: Liang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002295:Carcinoma, Transitional Cell / Q000235:genetics*; D005260:Female; D016158:Genes, p53; D011905:Genes, ras; D006801:Humans; D008297:Male; D008875:Middle Aged; D017354:Point Mutation; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis*; D016283:Proto-Oncogene Proteins p21(ras) / Q000096:biosynthesis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis; D001749:Urinary Bladder Neoplasms / Q000235:genetics*
chemical_list: D011518:Proto-Oncogene Proteins; D016283:Proto-Oncogene Proteins p21(ras); D018719:Erb-b2 Receptor Tyrosine Kinases; D016159:Tumor Suppressor Protein p53; C501009:HRAS protein, human